Skip to main content
. 2020 Mar 13;104(12):1755–1761. doi: 10.1136/bjophthalmol-2019-315726

Figure 4.

Figure 4

(A) Alterations of proportions of eyes which received bevacizumab (black circle), ranibizumab (white circle) or aflibercept (grey circle) to eyes which received antivascular endothelial growth factor agents. (B) Alterations of proportions of eyes which received as intravitreal (black square) or subtenon (white square) injection to eyes which received local corticosteroids.